{"id":4204,"date":"2024-03-27T06:03:26","date_gmt":"2024-03-27T13:03:26","guid":{"rendered":"https:\/\/grail.com\/?post_type=press-release&#038;p=4204"},"modified":"2024-03-27T06:03:29","modified_gmt":"2024-03-27T13:03:29","slug":"grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting","status":"publish","type":"press-release","link":"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/","title":{"rendered":"GRAIL Presents New Data on Galleri\u00ae and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting"},"content":{"rendered":"\n<p class=\"has-text-align-center base-block\"><em>New Data Will Highlight Use of GRAIL\u2019s Targeted Methylation Platform Across Early Cancer Detection and Precision Oncology<\/em><\/p>\n\n\n\n<p class=\"has-text-align-center base-block\"><em>Longer-term Data Underscore the Potential Value of GRAIL\u2019s Galleri<sup>\u00ae<\/sup> for Repeat Screening for Clinically Significant Cancers\u00a0<\/em><\/p>\n\n\n\n<p class=\"has-text-align-center base-block\"><\/p>\n\n\n\n<p class=\"base-block\"><strong>MENLO PARK, Calif., Mar. 27, 2024<\/strong> \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data on the clinical utility of its Methylation Platform across the cancer continuum, and the impact of multi-cancer early detection (MCED) testing in guiding diagnostic evaluation at the&nbsp;American Association for Cancer Research (AACR) Annual Meeting in San Diego, Calif., April 5-10, 2024.<\/p>\n\n\n\n<p class=\"base-block\">\u201cThe data we are presenting at AACR continue to support the potential of GRAIL\u2019s Methylation Platform to transform cancer care and the potential benefits of population-scale asymptomatic (or early) cancer detection,\u201d said Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL. \u201cOur longer-term research demonstrates that adding MCED tests like Galleri to guideline-recommended screenings can help direct diagnostic evaluation and underscores the potential value of repeat MCED screening. Additionally, new data from our Methylation Platform suggests the ability to identify relevant cancer subtypes using a single blood test, helping to enable precision medicine and biomarker discovery.\u201d&nbsp;<\/p>\n\n\n\n<p class=\"base-block\">In the MCED setting, GRAIL is honored to present 3 <strong>oral presentations<\/strong> at AACR:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list base-block\">\n<li class=\"base-block\">Demonstrating the first real-world evaluation of repeat MCED \/ Galleri testing showing the potential value of adding repeat MCED screening. The timeframe for repeat testing occurred 10-18 months from initial MCED testing.&nbsp;<\/li>\n\n\n\n<li class=\"base-block\">Exhibiting 4-year overall survival follow-up demonstrating the prognostic significance of detecting cancer with a methylation-based cfDNA platform like Galleri.<\/li>\n\n\n\n<li class=\"base-block\">Illustrating data demonstrating the power of Galleri to preferentially detect high grade, clinically significant prostate cancer over indolent cases.&nbsp;&nbsp;<\/li>\n<\/ul>\n\n\n\n<p class=\"base-block\">In the precision oncology setting, GRAIL will discuss the adaptability of its Methylation Platform in identifying cancer histological and molecular subtypes through blood samples.&nbsp;<\/p>\n\n\n\n<p class=\"base-block\"><strong>Oral Presentations<\/strong><strong>&nbsp;<\/strong><\/p>\n\n\n\n<p class=\"base-block\"><strong>Title:<\/strong> Early Real-World Experience with Repeat Multi-Cancer Early Detection (MCED) Testing<br><strong>Abstract Number:<\/strong> #3891<br><strong>Session Category:<\/strong> Clinical Research<br><strong>Session Title:<\/strong> Application of Real-World Evidence to Cancer Care<br><strong>Date\/Time:<\/strong> Monday, Apr. 8, 2024 from 2:30 PM &#8211; 4:30 PM<br><strong>Location:<\/strong> Room 6 CF &#8211; Upper Level &#8211; Convention Center<\/p>\n\n\n\n<p class=\"base-block\"><strong>Title:<\/strong> A Targeted Methylation-Based Multi-Cancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer and Minimizes Overdiagnosis<br><strong>Abstract Number:<\/strong> #1264<br><strong>Session Category:<\/strong> Prevention \/ Early Detection \/ Interception<br><strong>Session Title:<\/strong> Multi-Cancer Early Detection Testing: Where Are We?<br><strong>Date\/Time:<\/strong> Sunday, Apr. 7, 2024 from 3:00 PM &#8211; 5:00 PM<br><strong>Location:<\/strong> Room 28 &#8211; Upper Level &#8211; Convention Center<\/p>\n\n\n\n<p class=\"base-block\"><strong>Title:<\/strong> Prognostic Significance of Blood-Based Multi-Cancer Detection in Cell-Free DNA: 4-Year Outcomes Analysis<br><strong>Abstract Number:<\/strong> #3895<br><strong>Session Category:<\/strong> Clinical Research<br><strong>Session Title:<\/strong> Early Detection and Progression Biomarkers<br><strong>Date\/Time:<\/strong> Monday, Apr. 8, 2024 from 2:30 PM &#8211; 4:30 PM<br><strong>Location: <\/strong>Ballroom 6 B &#8211; Upper Level &#8211; Convention Center<\/p>\n\n\n\n<p class=\"base-block\"><strong>Poster Sessions<\/strong><\/p>\n\n\n\n<p class=\"base-block\"><strong>Title:<\/strong> PATHFINDER 2: A Prospective Study to Evaluate Safety and Performance of a Multi-Cancer Early Detection Test in a Population Setting<br><strong>Abstract Number:<\/strong> #4784<br><strong>Session Category:<\/strong> Prevention \/ Early Detection \/ Interception<br><strong>Session Title:<\/strong> Population-Based Screening<br><strong>Date\/Time:<\/strong> Tuesday, Apr. 9, 2024 from 9:00 AM &#8211; 12:30 PM<br><strong>Location:<\/strong> Poster Section 32<\/p>\n\n\n\n<p class=\"base-block\"><strong>Title:<\/strong> Identification of Cancer Subtypes with a ctDNA-based Targeted Methylation Assay<br><strong>Abstract Number:<\/strong> #7566<br><strong>Session Category:<\/strong> Clinical Research<br><strong>Session Title:<\/strong> Molecular Biology in Clinical Oncology: Characterizing and Modulating Epigenetics and Gene Expression<br><strong>Date\/Time:<\/strong> Wednesday, Apr. 10, 2024 from 9:00 AM &#8211; 12:30 PM<br><strong>Location: <\/strong>Poster Section 43<\/p>\n\n\n\n<p class=\"base-block\"><strong>Title: <\/strong>Most Cancer Deaths are Unaddressed by Current Screening Paradigms<br><strong>Abstract Number: <\/strong>#6075<br><strong>Session Category:<\/strong> Prevention \/ Early Detection \/ Interception<br><strong>Session Title:<\/strong> Biomarker-Based Screening<br><strong>Date\/Time:<\/strong> Tuesday, Apr. 9, 2024 from 1:30 PM &#8211; 5:00 PM<br><strong>Location:<\/strong> Poster Section 31<\/p>\n\n\n\n<p class=\"base-block\"><strong>Title:<\/strong> Association of Circulating Free DNA (cfDNA) Maximum Variant Allele Frequency (mVAF) Levels with Clinical Outcomes in Patients (pts) with Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) Treated with Pembrolizumab (pembro) + Chemotherapy (chemo) in the Phase 2 KEYNOTE-782 Trial<br><strong>Abstract Number:<\/strong> #LB107<br><strong>Session Category:<\/strong> Clinical Research<br><strong>Session Title:<\/strong> Late-Breaking Research: Clinical Research 1<br><strong>Date\/Time:<\/strong> Monday, Apr. 8, 2024 from 9:00 AM &#8211; 12:30 PM<br><strong>Location:<\/strong> Poster Section 51<\/p>\n\n\n\n<p class=\"base-block\"><strong>About GRAIL<\/strong><br>GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL\u2019s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission.<\/p>\n\n\n\n<p class=\"base-block\">For more information, visit <a href=\"https:\/\/grail.com\/\">grail.com<\/a>.<\/p>\n\n\n\n<p class=\"base-block\"><strong>About Galleri\u00ae<\/strong><br>The Galleri multi-cancer early detection test is a new proactive tool to screen for cancer. It is a blood test that can help screen for many of the deadliest cancers that don\u2019t have recommended screening today, such as pancreatic, esophageal, ovarian, and liver.* The Galleri test can identify DNA shed by cancer cells (unique \u201cfingerprints\u201d) to screen for some of the deadliest cancers before they become symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test provides direction to doctors on the cancer&#8217;s origin and helps guide next steps for diagnosis. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is recommended for people over the age of 50, or those with an elevated risk for cancer due to genetics, family history, environmental exposure, or other risk factors.**<\/p>\n\n\n\n<p class=\"base-block\">For more information, visit <a href=\"https:\/\/www.galleri.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">galleri.com<\/a>.<\/p>\n\n\n\n<p class=\"base-block\">*Editor\u2019s note: Sensitivity in <a href=\"https:\/\/www.annalsofoncology.org\/article\/S0923-7534(21)02046-9\/fulltext\" target=\"_blank\" rel=\"noreferrer noopener\">study<\/a> participants with \u2013<br>Pancreas cancer: 83.7% overall (61.9% stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV). Esophagus cancer 85.0% overall (12.5% stage I, 64.7% stage II, 94.7% stage III, 100% stage IV). Ovary cancer: 83.1% overall (50.0% stage I, 80.0% stage II, 87.1% stage III, 94.7% stage IV). Liver\/bile duct cancer: 93.5% overall (100% stage I, 70.0% stage II, 100% stage III, 100% stage IV).<\/p>\n\n\n\n<p class=\"base-block\">** Galleri has not been studied in people under 50 years of age with additional risk factors.<\/p>\n\n\n\n<p class=\"base-block\"><strong>Important Galleri Safety Information<br><\/strong>The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.<\/p>\n\n\n\n<p class=\"base-block\">Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of \u201cCancer Signal Not Detected\u201d does not rule out cancer. A test result of \u201cCancer Signal Detected\u201d requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.<\/p>\n\n\n\n<p class=\"base-block\">If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.<\/p>\n\n\n\n<p class=\"base-block\"><strong>Laboratory\/Test Information<br><\/strong>GRAIL\u2019s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL\u2019s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Data Will Highlight Use of GRAIL\u2019s Targeted Methylation Platform Across Early Cancer Detection and Precision Oncology Longer-term Data Underscore the Potential Value of GRAIL\u2019s Galleri\u00ae for Repeat Screening for Clinically Significant Cancers\u00a0 MENLO PARK, Calif., Mar. 27, 2024 \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can [&hellip;]<\/p>\n","protected":false},"featured_media":3500,"parent":0,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":true,"footnotes":""},"class_list":["post-4204","press-release","type-press-release","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GRAIL Presents New Data on Galleri\u00ae and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting - GRAIL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GRAIL Presents New Data on Galleri\u00ae and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting - GRAIL\" \/>\n<meta property=\"og:description\" content=\"New Data Will Highlight Use of GRAIL\u2019s Targeted Methylation Platform Across Early Cancer Detection and Precision Oncology Longer-term Data Underscore the Potential Value of GRAIL\u2019s Galleri\u00ae for Repeat Screening for Clinically Significant Cancers\u00a0 MENLO PARK, Calif., Mar. 27, 2024 \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"GRAIL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/grailbio\/\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-27T13:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/grail.com\/wp-content\/uploads\/2023\/06\/Grail-B-Roll-_01_05.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@grailbio\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/\",\"url\":\"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/\",\"name\":\"GRAIL Presents New Data on Galleri\u00ae and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting - GRAIL\",\"isPartOf\":{\"@id\":\"https:\/\/grail.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2023\/06\/Grail-B-Roll-_01_05.jpg\",\"datePublished\":\"2024-03-27T13:03:26+00:00\",\"dateModified\":\"2024-03-27T13:03:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/#primaryimage\",\"url\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2023\/06\/Grail-B-Roll-_01_05.jpg\",\"contentUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2023\/06\/Grail-B-Roll-_01_05.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/grail.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GRAIL Presents New Data on Galleri\u00ae and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/grail.com\/#website\",\"url\":\"https:\/\/grail.com\/\",\"name\":\"GRAIL\",\"description\":\"Detect cancer early, when it can be cured\",\"publisher\":{\"@id\":\"https:\/\/grail.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/grail.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/grail.com\/#organization\",\"name\":\"GRAIL, LLC\",\"url\":\"https:\/\/grail.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/grail.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png\",\"contentUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png\",\"width\":512,\"height\":512,\"caption\":\"GRAIL, LLC\"},\"image\":{\"@id\":\"https:\/\/grail.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/grailbio\/\",\"https:\/\/x.com\/grailbio\",\"https:\/\/www.linkedin.com\/company\/grail-inc.\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GRAIL Presents New Data on Galleri\u00ae and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting - GRAIL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/","og_locale":"en_US","og_type":"article","og_title":"GRAIL Presents New Data on Galleri\u00ae and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting - GRAIL","og_description":"New Data Will Highlight Use of GRAIL\u2019s Targeted Methylation Platform Across Early Cancer Detection and Precision Oncology Longer-term Data Underscore the Potential Value of GRAIL\u2019s Galleri\u00ae for Repeat Screening for Clinically Significant Cancers\u00a0 MENLO PARK, Calif., Mar. 27, 2024 \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can [&hellip;]","og_url":"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/","og_site_name":"GRAIL","article_publisher":"https:\/\/www.facebook.com\/grailbio\/","article_modified_time":"2024-03-27T13:03:29+00:00","og_image":[{"width":1920,"height":1080,"url":"http:\/\/grail.com\/wp-content\/uploads\/2023\/06\/Grail-B-Roll-_01_05.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@grailbio","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/","url":"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/","name":"GRAIL Presents New Data on Galleri\u00ae and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting - GRAIL","isPartOf":{"@id":"https:\/\/grail.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/#primaryimage"},"image":{"@id":"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2023\/06\/Grail-B-Roll-_01_05.jpg","datePublished":"2024-03-27T13:03:26+00:00","dateModified":"2024-03-27T13:03:29+00:00","breadcrumb":{"@id":"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/#primaryimage","url":"https:\/\/assets.grail.com\/wp-content\/uploads\/2023\/06\/Grail-B-Roll-_01_05.jpg","contentUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2023\/06\/Grail-B-Roll-_01_05.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/grail.com\/press-releases\/grail-presents-new-data-on-galleri-and-its-methylation-platform-at-the-annual-american-association-for-cancer-research-aacr-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/grail.com\/"},{"@type":"ListItem","position":2,"name":"GRAIL Presents New Data on Galleri\u00ae and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting"}]},{"@type":"WebSite","@id":"https:\/\/grail.com\/#website","url":"https:\/\/grail.com\/","name":"GRAIL","description":"Detect cancer early, when it can be cured","publisher":{"@id":"https:\/\/grail.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/grail.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/grail.com\/#organization","name":"GRAIL, LLC","url":"https:\/\/grail.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/grail.com\/#\/schema\/logo\/image\/","url":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png","contentUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png","width":512,"height":512,"caption":"GRAIL, LLC"},"image":{"@id":"https:\/\/grail.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/grailbio\/","https:\/\/x.com\/grailbio","https:\/\/www.linkedin.com\/company\/grail-inc.\/"]}]}},"_links":{"self":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release\/4204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/types\/press-release"}],"version-history":[{"count":0,"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release\/4204\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/media\/3500"}],"wp:attachment":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/media?parent=4204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}